Literature DB >> 1315367

Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses.

J T Wang1, T H Wang, J C Sheu, J T Lin, D S Chen.   

Abstract

In a prospective study of posttransfusion hepatitis, 14 patients who were diagnosed with posttransfusion hepatitis C were enrolled randomly for the study of hepatitis C virus (HCV) RNA in saliva. Saliva and serum samples were collected on the same day. Spouses of 11 married patients were also tested for anti-C100 and HCV RNA. Paired serum and saliva samples were tested for HCV RNA by a nested polymerase chain reaction (PCR). Two primer pairs specific for the non-coding region of HCV were used for the PCR and a oligonucleotide sequence between the primers was used as the probe for Southern hybridization. Six patients were positive for HCV RNA by first round PCR amplification and an additional four patients were detected after second round PCR. All patients were negative for HCV RNA in saliva after first round PCR, while seven were positive after second round PCR amplification. All seven patients were positive for HCV RNA in paired serum samples. HCV RNA was detectable in saliva from 1 week to 38 months after the onset of hepatitis. All spouses were negative for anti-C100 and HCV RNA. We conclude that HCV RNA is present in the saliva of approximately half of patients with acute and chronic hepatitis C, and the presence of HCV RNA correlates with HCV viremia. The efficiency of HCV transmission is low among spouses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315367     DOI: 10.1002/jmv.1890360106

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  HCV transmission in family members of subjects with HCV related chronic liver disease.

Authors:  L Demelia; E Vallebona; R Poma; G Sanna; G Masia; R C Coppola
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

Review 3.  Nonhepatic manifestations and combined diseases in HCV infection.

Authors:  S J Hadziyannis
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners.

Authors:  P Fabris; D Infantolino; M R Biasin; G Marchelle; E Venza; V Terribile Wiel Marin; P Benedetti; G Tositti; V Manfrin; F de Lalla
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

5.  Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients.

Authors:  Tetsuro Suzuki; Kazuhiko Omata; Tazuko Satoh; Takahiro Miyasaka; Chiaki Arai; Munehiro Maeda; Tomonori Matsuno; Tatsuo Miyamura
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 6.  The clinical virology of hepatitis C virus.

Authors:  W L Irving
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

7.  Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan.

Authors:  Eskandar Hajiani; Rahim Masjedizadeh; Jalal Hashemi; Mehrdad Azmi; Tahereh Rajabi
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

8.  Correlation of hepatitis C antibody levels in gingival crevicular fluid and saliva of hepatitis C seropositive hemodialysis patients.

Authors:  Gökhan Açıkgöz; Murat Inanç Cengiz; Ilker Keskiner; Sereften Açıkgöz; Murat Can; Aydan Açıkgöz
Journal:  Int J Dent       Date:  2009-09-10

Review 9.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

10.  Prevalence of antibodies to hepatitis C virus among family members of patients with chronic hepatitis C.

Authors:  N Napoli; G Fiore; F Vella; G Fera; O Schiraldi
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.